|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
C difficile test gives results within 20 minutes
|
|
Oxoid
: 18 March, 2010 (New Product) |
|
|
Oxoid is now offering a Clostridium difficile (C difficile) test for that provides results to healthcare professionals in just 20 minutes. |
|
|
The Remel Xpect C difficile Toxin A/B Test, a valuable diagnostic tool for use in the rapid detection of Clostridium difficile infection (CDI), is easy to use and provides accurate and reliable results. The speed and convenience enables healthcare professionals to quickly and decisively initiate appropriate patient care and Infection control procedures.
Clostridium difficile infection continues to be a major concern across Europe. With each case costing between Euros 5000 and Euros 15,000, the financial impact of this pathogen on the European Union could exceed Euros 3,000 million every year. In England, reporting of CDI in patients over 65 has been mandatory since 2004, and in patients more than two years of age it has been required in all acute NHS hospitals since 2007. Although the number of cases reported in England declined in the last financial year (2008/2009), C difficile was still involved in almost 6000 deaths.
Elderly and immunocompromised patients who have recently received antibiotic therapy are most at risk of C difficile-associated diarrhoea (CDAD), and infection can spread quickly throughout hospital wards and other healthcare institutions. The emergence of a highly virulent C difficile strain (ribotype 027) in Canada, North America and Europe has contributed to multiple outbreaks of severe disease in hospitals and care homes. Recent guidelines recommend that, when CDI is suspected, a stool sample should be tested for the presence of C difficile toxins immediately. Early diagnosis is recognized as one of several factors (including surveillance, education and Infection control measures) that combine to prevent the spread of CDI.
The Xpect Clostridium difficile Toxin A/B Test allows the direct detection of both C difficile toxins A and B in faecal samples. This is important since A-/B+ strains of C difficile have been linked to CDAD8-11. Diluted sample is simply mixed with a conjugate buffer and added to the test cassette. Within 20 minutes, the result is clearly visible and easily interpreted. No specialized equipment or expertise is required.
Xpect Clostridium difficile Toxin A/B test is suitable for use in laboratories of any size. This is particularly important since the significance of community-acquired CDI is increasingly recognized. Rapid testing may help healthcare institutions limit the spread of disease. Michelle Holland, Oxoid Senior Product Manager said: “Early diagnosis of CDI is essential for the prevention and containment of outbreaks. The speed and convenience of Xpect Clostridium difficile Toxin A/B test allows more laboratories and healthcare facilities to test for this rapidly spreading pathogen immediately, giving them faster results and the opportunity to respond quickly and efficiently to a positive result.”
In addition to the Xpect test for C. difficile toxins A and B, Oxoid also offers the Remel ProSpecT C difficile Toxin A/B Microplate Assay as part of a range of assays for the direct detection of enteric pathogens, including viruses and parasites. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
